Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300924 · ClinicalTrials.gov registry record · Phase 3
A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
A Phase 3 study of Migraine, sponsored by Diamond Headache Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 7
- Study locations
NCT00300924: Completed Phase 3 study of Migraine, sponsored by Diamond Headache Clinic.
NCT00300924 is a Phase 3 study of Migraine that has completed, run by Diamond Headache Clinic. The registered enrollment target is 200 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300924, a Phase 3 study of Migraine, has completed, sponsored by Diamond Headache Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.
Conditions Studied
Interventions
- DRUG Rizatriptan co-administered with Acetaminophen
Study Locations (7)
Missouri
- Clinvest - Springfield
- Mercy Health Research - St Louis
California
- SanFrancisco Headache Clinic - San Francisco
Illinois
- Diamond Headache Clinic - Chicago
Michigan
- Westside Family Medical Center - Kalamazoo
New York
- Elkind Headache Center - Mount Vernon
Ohio
- ClinExcel - West Chester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00300924 record still lists
NCT00300924 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Rizatriptan co-administered with Acetaminophen is the first listed.
NCT00300924 lists 7 locations in 6 states (Missouri, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT00300924 about?
NCT00300924 is a clinical study titled "A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine". The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.
What is the current status of trial NCT00300924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-03. Estimated completion is 2007-01.
What conditions does trial NCT00300924 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00300924?
The interventions under investigation include: Rizatriptan co-administered with Acetaminophen (DRUG).
Who is sponsoring clinical trial NCT00300924?
This trial is sponsored by Diamond Headache Clinic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300924 being conducted?
This trial has 7 study locations across California, Illinois, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00300924's enrollment target sits among peer trials
200 38th of 102 higher than 62 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia